February 21, 2007Open Access
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
Key Points
Key points are not available for this paper at this time.
Abstract
The reduction in death from all causes among patients with COPD in the combination-therapy group did not reach the predetermined level of statistical significance. There were significant benefits in all other outcomes among these patients. (ClinicalTrials.gov number, NCT00268216 ClinicalTrials.gov.).
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
P
Peter Calverley
University of Liverpool
J
Julie A. Anderson
GC Systems (United States)
Bartolomé R. Celli
Boston University
Journals
New England Journal of Medicine
Actions
Institutions
University of Liverpool
St George's, University of London
Research Triangle Park Foundation
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...